Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC2 | O75106 | 2/20 | 0.58 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.55 |
| ▸ | CTBP2 | P56545 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | PKM | P14618 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | GLS | O94925 | 1/20 | 0.50 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.50 |
| ▸ | ANO1 | Q5XXA6 | 1/20 | 0.49 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.49 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.49 |
| ▸ | CACNA1I | Q9P0X4 | 1/20 | 0.49 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.49 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.49 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7194491 | 0.87 | AOC2 (0.67) | AOC2ALDH1A1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL16905381 | 0.84 | HDAC8 (0.60) | MAPK8L3MBTL1NPC1CTBP2ALDH1A1 | |
| SCHEMBL13329815 | 0.84 | L3MBTL1 (0.56) | MAPK8L3MBTL1NPC1CTBP2ALDH1A1 | |
| SCHEMBL1947883 | 0.81 | ALDH1A1 (0.61) | MAPK8L3MBTL1NPC1ALDH1A1PKM | |
| SCHEMBL30598810 | 0.81 | NPC1 (0.61) | MAPK8L3MBTL1NPC1CTBP2ALDH1A1 | |
| SCHEMBL13753360 | 0.81 | NPC1 (0.61) | MAPK8L3MBTL1NPC1CTBP2ALDH1A1 | |
| SCHEMBL14679160 | 0.80 | NPC1 (0.57) | MAPK8L3MBTL1NPC1CTBP2ALDH1A1 | |
| SCHEMBL2951157 | 0.80 | AOC2 (0.59) | AOC2CTBP2ALDH1A1PKMCYP1A2 | |
| SCHEMBL27208476 | 0.80 | AOC2 (0.59) | AOC2CYP1A2CYP3A4CYP2C9GLS | |
| SCHEMBL27099073 | 0.80 | AOC2 (0.59) | AOC2ALDH1A1CYP1A2CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11912687-B2 | 3,4,5-trisubstituted-1,2,4-triazoles and 3,4,5-trisubstituted-3-thio-1,2,4-triazoles and uses thereof | Board of Trustees of the Southern Illinois University (US) | 2024-02-27 | — | — | US | disclosed |
| WO-2023161296-A1 | CONJUGATION METHOD INVOLVING A TRANSGLUTAMINASE AT THE FC REGION COMPRISING A TRIMMED N-GLYCAN | ADC THERAPEUTICS SA (CH) | 2023-08-31 | — | — | WO | disclosed |
| CN-116655536-A | Class N 1 -aryl-3-fluoroalkyl-5-fluoropyrazole compound, and preparation method and application thereof | 天津大学 | 2023-08-29 | — | — | CN | disclosed |
| EP-3838903-A1 | PYRROLO[2,3-D]PYRIMIDINE DERIVATIVE AS JANUS KINASE INHIBITOR | Incyte Holdings Corporation (US) | 2021-06-23 | — | — | EP | disclosed |
| EP-3466953-A1 | PYRROLO[2,3-D]PYRIMIDINE DERIVATIVE AS JANUS KINASE INHIBITOR | Incyte Holdings Corporation (US) | 2019-04-10 | — | — | EP | disclosed |
| EP-3184526-A1 | PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES AS JANUS KINASE INHIBITOR | Incyte Holdings Corporation (US) | 2017-06-28 | — | — | EP | disclosed |
| US-9556152-B2 | Heterocyclic amides as kinase inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-01-31 | — | — | US | disclosed |
| EP-2155728-B1 | HETEROCYCLIC INDAZOLE DERIVATIVES | MERCK PATENT GMBH (DE) | 2015-07-29 | — | — | EP | disclosed |
| US-8334309-B2 | Heterocyclic indazole derivatives | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2012-12-18 | — | — | US | disclosed |
| US-20110190355-A1 | HETEROCYCLIC INDAZOLE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2011-08-04 | — | — | US | disclosed |
| US-6001811-A | TREATMENT OF ADULT RESPIRATORY DISTRESS SYNDROME, SEPSIS, MULTIPLE ORGAN FAILURE | CORTECH INC. (US) | 1999-12-14 | — | — | US | disclosed |
| US-5998379-A | USEFUL AS INHIBITORS OF SERINE PROTEASES, IN PARTICULAR HUMAN NEUTROPHIL ELASTASE, TREATMENT OF ADULT RESPIRATORY DISTRESS SYNDROME, SEPTIC SHOCK, AND MYOCARDIAL ISCHEMIA-REPERFUSION INJURY | CORTECH INC. (US) | 1999-12-07 | — | — | US | disclosed |
| WO-1999054317-A1 | CYSTEINE PROTEASE INHIBITORS | CORTECH INC. (US) | 1999-10-28 | — | — | WO | disclosed |
| WO-1998049190-A9 | SUBSTITUTED OXADIAZOLE CYSTEINE PROTEASE INHIBITORS | CORTECH INC (US) | 1999-04-15 | — | — | WO | disclosed |
| US-5891852-A | Serine protease inhibitors-cycloheptane derivatives | CORTECH, INC. (US) | 1999-04-06 | — | — | US | disclosed |
| US-5869455-A | SUBSTITUTED OXADIAZOLE, THIADIAZOLE AND TRIAZOLE PEPTOIDS WHICH ARE USEFUL AS INHIBITORS OF HUMAN NEUTROPHIL ELASTASE | CORTECH, INC. (US) | 1999-02-09 | — | — | US | disclosed |
| US-5861380-A | OXADIAZOLE, THIADIAZOLE AND TRIAZOLE PEPTOIDS AS INHIBITORS OF HUMAN NEUTROPHIL ELASTASE; ADULT RESPIRATORY DISTRESS SYNDROME; ANTIARTHRITIC,-INFLAMMATORY,-ISCHEMIC,-TUMOR AND -CARCINOGENIC AGENTS AND OTHER HNE-MEDIATED CONDITIONS | CORTECH, INC. (US) | 1999-01-19 | — | — | US | disclosed |
| WO-1998049190-A2 | SUBSTITUTED OXADIAZOLE CYSTEINE PROTEASE INHIBITORS | CORTECH, INC. (US) | 1998-11-05 | — | — | WO | disclosed |
| US-5807829-A | RESPIRATORY SYSTEM DISORDERS; SESPIC SHOCK; ORGAN FAILURE | CORTECH, INC. (US) | 1998-09-15 | — | — | US | disclosed |
| US-5801148-A | Serine protease inhibitors-proline analogs | CORTECH, INC. (US) | 1998-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190355-A1 | HETEROCYCLIC INDAZOLE DERIVATIVES | SGK3, SGK2, SGK1 | AOC2 4406/4885MAPK8 1602/4885L3MBTL1 1193/4885 |
| US-11912687-B2 | 3,4,5-trisubstituted-1,2,4-triazoles and 3,4,5-trisubstituted-3-thio-1,2,4-triazoles and uses thereof | SSTR4, SSTR5, SSTR3 | AOC2 2790/4885MAPK8 1883/4885L3MBTL1 4463/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.